The clinical efficacy of ATRA has been already proven in a consistent number of phase 1–4 clinical trials conducted on solid tumors and hematologic tumors, yet the therapeutic impact of ATRA administration in patients cohorts with NRF2 overactivation still waits to be fully elucidated. The gene discussed is NFE2L2; the disease is hematopoietic and lymphoid cell neoplasm.